Andere Sprachen AstraZeneca PLC

Aktien

886455

GB0009895292

AZN

Pharmazeutika

Markt geschlossen - London S.E. Andere Börsenplätze 17:35:08 17.07.2026			% 5 Tage	Veränd. 1. Jan.
12.594,00 ^GBX	-0,27 %		-1,87 %	-8,67 %

17.07.	WOCHENVORSCHAU/27. Juli bis 1. August (31. KW)	DJ
17.07.	Nordische Aktien in Nordamerika - Astra Zeneca sank um 0,3 %	FW

Andere Sprachen

16.07.	Illumina, Inc., Formation Bio, Astrazeneca, Merck, and Eli Lilly and Company Expand Billion Cell Atlas Alliance with New Ai Drug Developers
16.07.	Molecular Partners Doses First Patients in Phase 2 Study of Biliary Tract Cancer Therapy
16.07.	Keymed Biosciences Expects Return to Profit in H1
15.07.	Dizal Announces Global Exclusive License Agreement with AstraZeneca for Zegfrovy
15.07.	Innovent Biologics Shares Surge on Spero Deal That Could Be Worth $1.1 Billion
14.07.	US FDA approves Celcuity's breast cancer drug
14.07.	AstraZeneca PLC agreed to acquire worldwide rights to develop and commercialise Zegfrovy from Dizal Pharmaceutical Co., Ltd. for $1.5 billion.
14.07.	UK Shares Rise as Investors Weigh Middle East Tensions; BP Gains
14.07.	Where would AI lead Pharma in the long run?
14.07.	Global markets live: JPMorgan, BoA, Paramount, IBM, TSMC…
14.07.	Europese beurzen lager door oplopende olieprijs
14.07.	AstraZeneca Licenses Zegfrovy From Dizal in Up to $1.5 Billion Deal
14.07.	European Midday Briefing : Shares Fall, Oil Hits One-Month High on Middle East Tensions
14.07.	AstraZeneca Enters Exclusive Global License Agreement Fornovel Oral EGFR Inhibitor Zegfrovy for Lung Cancer with Dizal Pharmaceutical
14.07.	AstraZeneca buys worldwide rights to cancer drug for USD1.5 billion
14.07.	Dizal Pharmaceutical Co., Ltd. Grants Astrazeneca plc Worldwide Rights to Develop and Commercialise Zegfrovy
14.07.	UK Stocks-Factors to watch on July 14
14.07.	AstraZeneca acquiert des droits sur Zegfrovy de Dizal
14.07.	BP production falls; Astra lands USD1.5 billion deal
14.07.	Bourse : easyJet valide l'OPA, la fusion Warner-Paramount menacée
14.07.	AstraZeneca Enters Exclusive License Deal For Lung Cancer Drug Zegfrovy For Up to $1.5 Billion
14.07.	AstraZeneca : enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical
14.07.	AstraZeneca Signs Licensing Deal With Dizal for Lung Cancer Treatment
14.07.	AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical
14.07.	Trump a une nouvelle idée pour Ormuz